Tweets
Kaeley et al. Evaluation of success of RA treatment. 69% LDA, 17% MDA, 14% HDA. Common barriers - medication access 27%, non-adherence 20%, co-morbidities 20%, non-inflammatory pain 13% @rheumnow #ACR22 Abstr#0077 https://t.co/c7euuzSx1m https://t.co/9ZN14ph5kI
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
@AlexisOgdie at #ACR22:
Ab0189 Ignite 🔥
PEST screening in patients with PsO w/o diagnosis of PsA - captures pts at highest risk. Decrease QoL, higher co-morbdities
High sensitivity test for screening
But is it capturing other co-morbidities (obesity, depression?)
@RheumNow
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
What factors influence visit preferences in pts w/ rheumatic dse? @rheumarhyme @doktora_ging
Interesting findings by Dr MDanila et al:
👉In-person visits due to org/clinic level influences
👉#telemedicine visits due to individual level influences
#ACR22 @RheumNow ABST0193 https://t.co/HcCUeahH8L
sheila @RHEUMarampa ( View Tweet )
3 years 8 months ago
Pregnancy associated back pain and fatigue during 3rd trimester of pregnancy may affect accuracy of BASDAI score in women with AS. Morning stiffness has the highest classification value #ABS0374 #ACR22 @RheumNow https://t.co/DozZ6bxSU3
Olga Petryna @DrPetryna ( View Tweet )
3 years 8 months ago
Rhee et al. MRI can, and frequently does, visualise enhancement in multiple cranial arteries @rheumnow #ACR22 Abstr#0473 https://t.co/iTtvl2DSoi https://t.co/tUV2zYIO8y
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Brunetta et al. Is serum ANCA assoc malignancy? No @rheumnow #ACR22 Abstr#0450 https://t.co/dCJUZVvAqy https://t.co/K27Rk5tLSU
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Levinson et al. Comparative risks of Alzheimers in inflammatory diseases. SLE (OR 1.31) and IBD (OR 1.17) higher risk than controls, RA, or PsO/PsA @rheumnow #ACR22 Abstr#0062 https://t.co/PbRa033e0L https://t.co/ENycKG4cyQ
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Mechanistic target of rapamycin (mTOR) inhibitors may be successful tx of sarcoidosis. Abs 0136 is an interesting study yielding more questions than answers. #ACR22 @RheumNow https://t.co/0Q260CGw3r https://t.co/LepPOrq7Gv
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Benavides et al. "Optimisation" of tocilizumab in GCA. Dose decreased or interval increased. 231 patients. Sustained remission 78.2% optimised group (vs 66.7%). @rheumnow #ACR22 Abstr#0474 https://t.co/jPRy4RjfJA https://t.co/b1CP8pFwhJ
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Adding MTX to Pegloticase for 52 wks in gout
â—¦ Improved response rate by 30%
â—¦ Reduced discontinuation rate by 40%
â—¦ Greater resolution of tophi by 20%
â—¦ Similar safety profile in MTX vs non-MTX groups
Botson J MIRROR RCT https://t.co/ifXLdvOv0K #ACR22 #ACRBest @RheumNow
Dr. Antoni Chan @synovialjoints ( View Tweet )
3 years 8 months ago
Fussner et al. Alpha1-antitrypsin alleles in AAV. Deficiency alleles in 16%. More likely MPA, MPO+. Less likely MSK symptoms, granulomatous disease @rheumnow #ACR22 Abstr#0439 https://t.co/Zi7H5UaolS https://t.co/Z04TvugnnE
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
#abs0380 #acr22 @rheumnow OM1 PsA cohort retro: PsA pts w/comorbidities &prior biologic use (both TNFi&SEC) respond well to IXE after 12 mo even w/monotherapy:IXE mono (82% pts) change in CDAI from BL to 6 mo -3.6 points& 12 mo -4.9 pts (statistically significant for both) https://t.co/5dRk86A9Xr
Olga Petryna @DrPetryna ( View Tweet )
3 years 8 months ago
